Marie Le Mercier

Dr. Marie Le Mercier

Antwerp University Hospital, Antwerp, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
GFGuy Froyen
Guy Froyen
MMMarie Le Mercier
Marie Le Mercier
ELEls Lierman
Els Lierman
KVKarl Vandepoele
Karl Vandepoele
FNFriedel Nollet
Friedel Nollet
AHAline Hébrant
Aline Hébrant
In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the default assay for the detection of somatic variants in solid as well as haematological tumours. Independent of the method, the final outcome is a list of variants that differ from the human genome reference sequence of which some may relate to the establishment of the tumour in the patient. A critical point towards a uniform patient management is the assignment of the biological contribution of each variant to the malignancy and its subsequent clinical impact in a specific malignancy. These so-called biological and clinical classifications of somatic variants are currently not standardized and are vastly dependent on the subjective analysis of each laboratory. This subjectivity can thus result in a different classification and subsequent clinical interpretation of the same variant. Therefore, the ComPerMed panel of Belgian experts in cancer diagnostics set up a working group with the goal to harmonize the biological classification and clinical interpretation of somatic variants detected by NGS. This effort resulted in the establishment of a uniform, two-level classification workflow system that should enable high consistency in diagnosis, prognosis, treatment and follow-up of cancer patients. Variants are first classified into a tumour-independent biological five class system and subsequently in a four tier ACMG clinical classification. Here, we describe the ComPerMed workflow in detail including examples for each step of the pipeline. Moreover, this workflow can be implemented in variant classification software tools enabling automatic reporting of NGS data, independent of panel, method or analysis software.

14 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LCLize Cuypers
Lize Cuypers
JBJannes Bode
Jannes Bode
KBKurt Beuselinck
Kurt Beuselinck
LLLies Laenen
Lies Laenen
KDKlaas Dewaele
Klaas Dewaele
EAEmmanuel André
Emmanuel André
From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information. A proposal to harmonize reporting of test results was drafted by the National Reference Centre (NRC) UZ/KU Leuven, distinguishing four categories of positivity based on RNA copies/mL. Pre-quantified control material was shipped to 124 laboratories with instructions to setup a standard curve to define thresholds per assay. For each assay, the mean Ct value and corresponding standard deviation was calculated per target gene, for the three concentrations (107, 105 and 103 copies/mL) that determine the classification. The results of 17 assays are summarized. This harmonization effort allowed to ensure that all Belgian laboratories would report positive PCR results in the same semi-quantitative manner to clinicians and to the national database which feeds contact tracing interventions.

25 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IHInke De Haes
Inke De Haes
ADAmélie Dendooven
Amélie Dendooven
MMMarie Le Mercier
Marie Le Mercier
PPPauline Puylaert
Pauline Puylaert
KVKatrien Vermeulen
Katrien Vermeulen
SASébastien Anguille
Sébastien Anguille
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the rapid and uncontrolled clonal growth of myeloid lineage cells in the bone marrow. The advent of oral, selective inhibitors of the B-cell leukemia/lymphoma-2 (BCL-2) apoptosis pathway, such as venetoclax, will likely induce a paradigm shift in the treatment of AML. However, the high cost of this treatment and the risk of additive toxicity when used in combination with standard chemotherapy represent limitations to its use and underscore the need to identify which patients are most—and least—likely to benefit from incorporation of venetoclax into the treatment regimen. Bone marrow specimens from 93 newly diagnosed AML patients were collected in this study and evaluated for BCL-2 protein expression by immunohistochemistry. Using this low-cost, easily, and readily applicable analysis method, we found that 1 in 5 AML patients can be considered as BCL-2−. In addition to a lower bone marrow blast percentage, this group exhibited a favorable molecular profile characterized by lower WT1 expression and underrepresentation of FLT3 mutations. As compared to their BCL-2+ counterparts, the absence of BCL-2 expression was associated with a favorable response to standard chemotherapy and overall survival, thus potentially precluding the necessity for venetoclax add-on.

7 September 2026 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EIElias Iturrospe
Elias Iturrospe
EBEva De Backer
Eva De Backer
MMMarie-Berthe Maes
Marie-Berthe Maes
KDKathleen Deiteren
Kathleen Deiteren
RFReinoud Flies
Reinoud Flies
CHCatharina van der Heijden
Catharina van der Heijden
We report the case of a patient with a de novo pathogenic germline variant causing GATA2 deficiency. GATA2 deficiency is a rare autosomal dominant inborn error of immunity caused by heterozygous lo...